b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">28694390</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>30</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>10</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2040-2058</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>22</Volume>\n                    <Issue>7</Issue>\n                    <PubDate>\n                        <Year>2017</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Antiviral therapy</Title>\n                <ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>613-618</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP3180</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barr\xc3\xa9 syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we investigated the in vitro susceptibility of geographically and temporally distinct Zika viruses against the RNA polymerase inhibitors, favipiravir (T-705) and ribavirin.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">The in vitro activity of each drug and a 1:1 mixture combination was assessed against five geographically and temporally distinct Zika strains by plaque reduction assay (PRA), the gold standard phenotypic method.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed that both drugs exhibit in vitro inhibitory activity against five different Zika strains isolated in different years and continents, with mean 50% inhibitory concentration (IC<sub>50</sub>) values of 35 \xc2\xb114 and 35 \xc2\xb120 \xc2\xb5M, respectively, by PRA. We did not observe a synergistic effect when both drugs were combined at the equimolar concentration (IC<sub>50</sub> =33 \xc2\xb111 \xc2\xb5M).</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that T-705 has the potential to be used in patients with complicated diseases and/or those individuals presenting with significant comorbidities.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Baz</LastName>\n                    <ForeName>Mariana</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research Center in Infectious Diseases of the CHU of Qu\xc3\xa9bec and Laval University, Qu\xc3\xa9bec City, QC, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Goyette</LastName>\n                    <ForeName>Nathalie</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research Center in Infectious Diseases of the CHU of Qu\xc3\xa9bec and Laval University, Qu\xc3\xa9bec City, QC, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Griffin</LastName>\n                    <ForeName>Bryan D</ForeName>\n                    <Initials>BD</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kobinger</LastName>\n                    <ForeName>Gary P</ForeName>\n                    <Initials>GP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research Center in Infectious Diseases of the CHU of Qu\xc3\xa9bec and Laval University, Qu\xc3\xa9bec City, QC, Canada.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Boivin</LastName>\n                    <ForeName>Guy</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research Center in Infectious Diseases of the CHU of Qu\xc3\xa9bec and Laval University, Qu\xc3\xa9bec City, QC, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>07</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Antivir Ther</MedlineTA>\n            <NlmUniqueID>9815705</NlmUniqueID>\n            <ISSNLinking>1359-6535</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000577">Amides</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>49717AWG6K</RegistryNumber>\n                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EW5GL2X7E0</RegistryNumber>\n                <NameOfSubstance UI="C462182">favipiravir</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D062211" MajorTopicYN="N">Spatio-Temporal Analysis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName>\n                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>\n                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>05</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>7</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>7</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>7</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28694390</ArticleId>\n            <ArticleId IdType="doi">10.3851/IMP3180</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'